Mingdian Tan

This paper develops a niclosamide sulfate prodrug, SSL-0024, which improves solubility and bioavailability, showing strong anti-tumor effects against hepatocellular carcinoma through multiple pathway inhibition.

This study identifies cytokines that enhance influenza vaccine antibody responses in human organoids and mice, showing their potential as adjuvants to improve vaccine efficacy.

This study develops a niclosamide prodrug (NIC-PS) with improved bioavailability and shows it targets VASN-TGFβ signaling to reduce HCC tumor volume and enhance therapeutic responses.